Pulsed estrogen therapy: Relieving climacteric symptoms, preventing postmenopausal bone loss

Climacteric

Volumn 5, Issue SUPPL. 2, 2002, Pages 32-39

  Palacios, S ^a  

^a Palacios Institute of Women's Health   (Spain)

Author keywords

Bone mass; Cardiovascular protection; Climacteric symptoms; Pulsed estrogen therapy

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR; CHOLESTEROL; ESTRADIOL; ESTROGEN; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLIMACTERIUM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; OSSIFICATION; OSTEOLYSIS; PALLIATIVE THERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SWEATING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; PULSE THERAPY, DRUG; RANDOMIZED CONTROLLED TRIALS;

EID: 0036387622     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41
2. Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6
3. Devissaguet JP, Brion N, Lhote O, Delobdne P. Pharmacokinetics of estradiol administered by nasal spray (S 21400) to postmenopausal women with comparison to transdermal and oral formulations. Eur J Drug Metab Pharmacokinetics 1999;24:265-71
4. Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change? Lancet 1994;343:649-53
5. Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13:688-703
6. Palacios S, Cifuentes I. Eficacia de la TRH en el síndrome climatérico. Rev Iberoam Menop 1999;1:17-22
7. Palacios S, Menendez C, Rodriguez A. Eficacia clínica de la THS con y sin veralipride en la sintomatología climatérica. Prog Obstet Gin 1993;36:31-6
8. Studd J, Pornel B, Marton I, et al. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 1999;353:1574-8
9. Mattsson LA, Christiansen C, Colan J, et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-52
10. Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart JM, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906-12
11. Rozenbaum H, Chevallier O, Moyal M, et al. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Climacteric 2002;5:in press
12. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990;592:263-71
13. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann NY Acad Sci 1990;592:193-203
14. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90
15. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993;23:466-73
16. Kenemans P, van Unnik GA, Mijatovic V, van der Mooren MJ. Perspectives in hormone replacement therapy. Maturitas 2001;38(Suppl 1):S41-8
17. Christiansen C. Hormone replacement therapy for the postmenopausal woman. Maturitas 2001;38(Suppl 1):S1-5
18. Christiansen C, Rodbro P, Tjellesen L. Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis. Acta Med Scand 1984;216:11-17
19. Waren M. HRT in elderly women. Clin Obstet Gynaecol 1996;39:912-32
20. Barzel US. Estrogens in the prevention and treatment of postmenopausal osteoporosis: a review. Am J Med 1988;85:847-50
21. Palacios S. Osteoporosis: prevention with estrogens in women over 60. Maturitas 1999;33:1-6
22. Quigley ME, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-23
23. Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983;309:1405-7
24. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD. Effects of intranasal 17β-estradiol on bone turnover and serum insulin-like growth factor in postmenopausal women. J Clin Endocrinol Metab 1999;84:2390-7
25. Tremolliéres F, Ribot C, Pornel B, Marianoswki P, Garnero P, Delmas PD. Postmenopausal bone loss is prevented by pulsed estrogen therapy: a comparison with the transdermal patch. Gynecol Endocrinol 2000; 14(Suppl 2):230